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Abstract
Background: Septic shock, defined as life-threatening organ dysfunction caused by a dysregulated host response to
infection, is a highly lethal condition that causes substantial morbidity and mortality among critically ill patients. One
of the hallmarks of sepsis is the excessive release of cytokines and other inflammatory mediators causing refractory
hypotension, tissue damage, metabolic acidosis and ultimately multiple organ failure. In this context, cytokine reduction
by hemoadsorption represents a new concept for blood purification, developed to attenuate the overwhelming
systemic levels of pro-inflammatory and anti-inflammatory mediators released in the early phase of sepsis.
Methods: In the present case series, we evaluated the impact of a new hemoadsorption device (CytoSorb) used as
adjunctive therapy, on hemodynamics and clinically relevant outcome parameters in 26 critically ill patients with septic
shock and in need of renal replacement therapy.
Results: We found that treatment of these patients with septic shock was associated with hemodynamic
stabilization and a reduction in blood lactate levels. Actual mortality in the overall patient population was lower
than mortality predicted by acute physiology and chronic health evaluation II (APACHE II). These effects seem to
be more pronounced in patients in whom therapy started within 24 h of sepsis diagnosis, whereas a delay in the
start of therapy was associated with a poor response to therapy in terms of reduction of catecholamine demand
and survival. Moreover, from our patient population, medical patients seemed to benefit more than post-surgical
patients in terms of survival. Treatment using the CytoSorb device was safe and well-tolerated with no device-
related adverse events during or after the treatment sessions.
Conclusion: Hemoadsorption using CytoSorb resulted in rapid hemodynamic stabilization and increased survival,
particularly in patients in whom therapy was started early. Given the positive clinical experience of this case
series, randomized controlled trials are urgently needed to define the potential benefits of this new treatment
option.
Keywords: Inflammation, Sepsis, Septic shock, Cytokines, Cytokine storm, CytoSorb, Hemoadsorption,
Hemoperfusion, Hemodynamics, Catecholamines
Background
Sepsis is defined as life-threatening organ dysfunction
caused by a dysregulated host response to infection and
its most severe state, septic shock, represents a highly le-
thal condition that causes substantial morbidity and mor-
tality among critically ill patients [1]. Despite considerable
advances in antibiotic therapy, resuscitative strategies,
ventilator management, and improved understanding of
the underlying pathophysiology, the incidence of septic
shock continues to increase and remains associated
with a high mortality rate, ranging from 30 to 50% and
more [2, 3]. An issue that is also of concern is the escal-
ating cost of sepsis-associated medical care, which has
been calculated to reach US$17 billion annually in the
USA [4] alone.
Early septic shock is predominantly the result of refrac-
tory hypotension [5] and high levels of cytokines excessively
released during the exaggerated immune response imma-
nent to the sepsis syndrome play an integral part in the
collapse of the vascular system. Prolonged hemodynamic
failure can cause further inflammation due to tissue damage
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related to ischemia/reperfusion and hypoperfusion of the
vital organs. Of note, the cumulative vasopressor load in
patients with sepsis is correlated with intensive care unit
(ICU) mortality, the occurrence of acute circulatory failure,
metabolic acidosis and renal failure [6].
In recent years, novel therapies have demonstrated a
positive effect on hemodynamics and mortality [7, 8],
while other approaches, despite appearing biologically
rational, have less positive results.
Hemofiltration for instance, representing a widely used
technique to manage renal failure, has been tested ex-
tensively in the setting of severe sepsis and septic shock
[9]. Several clinical studies suggest that high-volume
hemofiltration (HVHF) might decrease vasopressor re-
quirements, and improve hemodynamics and lactate
clearance [10]; however, the majority of controlled trials
have not had a clinically significant and sustained effect
on either cytokine removal or overall survival [11, 12].
In this context, cytokine reduction by hemoadsorp-
tion represents a new concept for blood purification,
developed to attenuate the overwhelming systemic
levels of pro-inflammatory and anti-inflammatory me-
diators released in the early phase of sepsis. Several
clinical and in vitro data have demonstrated that the
additional treatment with an extracorporeal cytokine
adsorber results in effective removal of toxic cytokine
levels and may be helpful in patients with septic mul-
tiple organ failure [13–16].
The CytoSorb whole blood adsorber is a CE-
approved medical device and its use is intended in
clinical situations in which cytokines are elevated.
CytoSorb therapy has been safely used in more than
9000 patients. The highly porous, biocompatible poly-
mer with its specific properties is capable of binding
a broad spectrum of hydrophobic compounds with a
molecular weight between 10 and 55 kDa, a range
where most cytokines reside. Removal of substances is
concentration dependent. While low cytokine plasma
concentrations are not affected, high cytokine plasma
levels are reduced effectively.
Mitzner et al. were among the first to study the effect
of CytoSorb as a blood purification technique in a pa-
tient with acute-on-chronic kidney failure and septic
shock [13]. To date, CytoSorb has also been successfully
applied in patients with post-cardiopulmonary bypass
systemic inflammatory response syndrome (SIRS) [17],
rhabdomyolysis-associated myoglobinemia [18] and in
liver failure [19]. Along with the effective removal of in-
flammatory mediators, the most prominent effect ob-
served with the use of CytoSorb is the improvement in
hemodynamics accompanied by a reduction in vasopressor
doses. In the present case series, we evaluated the impact
of CytoSorb, used as adjunctive therapy, on hemodynamics
and clinically relevant outcome parameters in 26 critically
ill patients with septic shock and in need of renal replace-
ment therapy.
Methods
This case series was conducted at the surgical-medical
intensive care unit of Emden hospital, Germany. All pa-
tients or their relatives gave signed informed consent for
retrospective data evaluation. The study protocol was
approved by the Ethics Committee of the General
Medical Council of Lower Saxony. We included patients
with an acute physiology and chronic health evaluation
II (APACHE II) score >25 and a diagnosis of septic
shock.
Patients with septic shock were identified using the in-
clusion criteria described in Bernard et al. [20]. Briefly,
patients were eligible for inclusion if they had a known
or suspected infection on the basis of clinical data at the
time of screening and if they met the following criteria
within a 24 h period: three or more signs of systemic in-
flammation and the sepsis-induced dysfunction of at
least two organs or organ systems. Patients excluded
from analysis were pregnant or breast-feeding women,
patients age <17 years and patients who were not ex-
pected to survive beyond 28 days because of an uncor-
rectable medical condition such as a poorly controlled
neoplasm or other moribund state end-stage diseases in
which death was perceived to be imminent.
Patients were initially treated following the Surviving
Sepsis Guidelines. Organ failure had to include acute
kidney injury (AKI) necessitating renal replacement ther-
apy. These criteria had to be fulfilled despite maximum
standard therapy including adequate fluid resuscitation
(following Kidney Disease Improving Global Outcomes
(KDIGO) guidelines) [21], differentiated catecholamine
therapy including administration of norepinephrine to
achieve mean arterial pressure (MAP) >60 mmHg, anti-
biotics at least 1 h after detection of septic shock (for an-
tibiotics administered see Table 1), and lung-protective
ventilation. If there was no decrease in norepinephrine
demand even after an additional corticoid treatment and
if the patient met the minimum criteria for AKI stage II
at this stage (serum creatinine 2.0–2.9 times baseline,
urine output <0.5 ml/kg/h for ≥12 h), continuous renal
replacement therapy (CRRT) in combination with Cyto-
Sorb therapy was initiated.
CRRT was performed in continuous veno-venous
hemodialysis (CVVHD) mode using a citrate-based
anticoagulation protocol (Multifiltrate CiCa; Fresenius
Medical Care, Bad Homburg, Germany). A CytoSorb
adsorber was then installed in line into the CRRT cir-
cuit in a pre-hemofilter position (AV1000; Fresenius
Medical Care). Blood flow rates were kept between 100
and 150 mL/minute while dialysis doses were in the
range of 20 to 30 mL/kg/h, according to standard care.
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All patients received a minimum of one CytoSorb
treatment and underwent additional treatments depend-
ing on their clinical response. Adsorbers were changed
every 24 h or every 12 h if there was no effect or only a
marginal effect within a certain amount of time (de-
crease of <20% in catecholamine demand within 24 h).
Treatment was continued until catecholamine demand
was stopped or until shock reversal, as defined by a de-
cline in catecholamine demand to 10% of the initial dose
prior to starting treatment or total cessation of catechol-
amines after the last CytoSorb treatment. If there was
more than one CytoSorb treatment, the subsequent
treatment was started immediately after termination of
the previous session. The numbers of treatments are
depicted in Table 1.
To assess the therapeutic impact of the combined
CRRT/CytoSorb treatment we calculated or collected
simplified acute physiology II (SAPS-II) score, sequential
organ failure assessment (SOFA) score, the demand for
norepinephrine to achieve a certain MAP (μg/h*mmHg-
1) and assessed blood lactate levels, before and after each
CytoSorb treatment. We also evaluated catecholamine-
free days (in relation to ICU days) and duration of extra-
corporeal organ support (mechanical ventilation, CRRT).
Furthermore, to differentiate the outcome of patients in
relation to delay in starting CytoSorb therapy, three slots
have been defined (time delay from sepsis diagnosis to
start of therapy up to 24 h, between 24 and 48 h or more
than 48 h). Intensive care and hospital length of stay
and ICU, 28-day and hospital survival were obtained
as outcome parameters. Tests of equal distribution of
the variables were carried out. All sets of data were
graphically presented using GraphPad Prism 5.01
software.
Results
From March 2014 to November 2016 we treated and
followed 26 consecutive patients with septic shock and
the onset of at least two organ failures within the previ-
ous 48 h due to acute infection from either abdominal
(post-surgical; n = 13) or pneumonic (medical; n = 13)
focus, with no improvement despite adequate standard
medical treatment. Patient characteristics and details on
the individual sources of infection are depicted in
Table 1. On admission to the ICU, the median APACHE
II score was 35. All patients received at least one Cyto-
Sorb treatment and received additional treatments (up
to five) according to the intensivist’s decision and as out-
lined in “Methods” (Table 1). The median number of
CytoSorb treatments in this population was three.
The combined application of CVVHD and CytoSorb
was associated with a pronounced decrease in catechol-
amine demand and stabilization of hemodynamics in the
overall patient population (Fig. 1, Table 2). To explain
these effects, we calculated the demand for norepineph-
rine necessary to achieve a certain MAP by simply divid-
ing the norepinephrine dose (μg/h) by the MAP (mmHg)
measured at the same time point. In general, vasopressor
Fig. 1 Effect of CytoSorb hemoadsorption on hemodynamics in relation to survival. Demand for norepinephrine to achieve a certain mean
arterial pressure (NOR/MAP) (μg/h*mmHg-1) before (pre) and after (post) CytoSorb treatments in the overall patient population and in 28-day, ICU,
and hospital survivors. In each Tukey boxplot the whiskers have equal lengths of 1.5 IQR. Dots represent outliers
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dosage was clearly reduced during the treatment by 67%
(Fig. 1). In parallel to the hemodynamic stabilization, the
blood lactate levels decreased by 26.4% when comparing
median levels before and after treatment (Fig. 2). There
was a sustained reduction in the demand for norepineph-
rine and in lactate blood levels, even beyond 72 h after the
last CytoSorb treatment.
We only saw marginal differences in the SAPS II
(decrease of 18.1%) and SOFA scores (decrease of 4.1%)
during and after therapy.
Shock reversal was observed in 10 patients (38.5%).
During the course of CytoSorb treatment, all patients
who survived to day 28 (n = 10) had reduction in cat-
echolamine demand to 0–29.2% (median 5.3%) of their
initial dose before the start of treatment, while patients
who did not survive to 28 days (n = 16) had no reduction
in the median catecholamine demand (102.6% of their
initial dose). The same was true for patients surviving
beyond ICU discharge (n = 7) (Fig. 1). Hospital survival
was greater in patients who initially had higher catechol-
amine demand compared to their non-surviving counter-
parts, but in whom catecholamine dosages were reduced
significantly during their treatments with continuous
veno-venous hemodialysis (CVVHD) and CytoSorb. These
effects were not related to a specific number of treatments
(i.e. patients who had five treatments also had reversal of
shock and survived).
The percentage of catecholamine-free days in the
seven ICU survivors was 68.29%, whereas non-survivors
only spent 7.5% of their ICU stay catecholamine-free. Of
note, one patient (age 17 years) who was admitted with
pneumonia and an APACHE II score of 29, and required
two CytoSorb treatments to reduce his catecholamine
demand to 10% of the initial dose (before starting ther-
apy), required catecholamine support until discharge.
Due to transfer to a tertiary center, he only had an ICU
and hospital stay of 2 days.
ICU and hospital survivors had a lower median APA-
CHE II score on inclusion in the study when compared
to non-survivors (29 vs. 37 and 29 vs. 36, respectively).
Mortality as predicted by APACHE II score in the over-
all patient population was 89.9%. The actual 28-day, ICU
and hospital mortality was 61.54%, 73.08% and 80.77%,
respectively.
Groups of patients starting therapy within <24 h, be-
tween 24 and 48 h or after >48 h had a median delay of
24 h, 48 h and 96 h, respectively. Disease severity in
our patients was not related to differences in delay in
starting therapy, i.e. patients treated early had a median
APACHE II score of 37, whereas patients starting treat-
ment between 24 and 48 h had an APACHE II score of
30.5 and those treated after 48 h had an APACHE II
score of 44 (Fig. 3). The SOFA score was lowest in the
early treatment group (median SOFA score of 11)
Fig. 2 Effect of CytoSorb hemoadsorption on blood lactate levels in relation to survival. Lactate levels (mg/dl) before (pre) and after (post)
CytoSorb treatments in the overall patient population and in 28-day, ICU, and hospital survivors. In each Tukey boxplot the whiskers have equal
lengths of 1.5 IQR. Dots represent outliers
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compared to the other groups (median score 14.5 in pa-
tients treated between 24 and 48 h and 14.0 in patients
treated after >48 h).
The hospital mortality rate was 69.23% when the start
of therapy was delayed by <24 h (92.3% predicted mor-
tality in these patients) (Table 3). Short-term 28-day
mortality in this subset of patients treated early was even
lower at 53.3%. Poor outcome was more frequent in
patients starting CytoSorb therapy late (87.5% of non-
survivors with a delay between 24 and 48 h and 100% in
non-survivors with a delay >48 h). The median start of
CytoSorb therapy in hospital non-survivors was much
later than in survivors (36 h vs. 24 h, respectively). All
ICU survivors who had been treated early left the
hospital alive, whereas none of the patients treated after
a delay >48 h did. In patients in whom treatment was
started early (<24 h), eventual 28-day survivors had a
reduction in catecholamine demand during the course
of their CytoSorb treatment(s) to 5.3% of their initial
dose before starting treatment. However, non-survivors
had a drastic increase in catecholamine demand at the
same time (225% of their initial dose).
Hospital mortality was 75% (predicted mortality 93.25%)
in post-surgical patients who started therapy early and it
was 60% (predicted mortality 87%) in patients with med-
ical pneumonia who started therapy early (Table 3). Re-
duction in catecholamine dosages was slower in medical
patients when compared to surgical patients in the group
of patients who started treatment early (14% vs. 40%, re-
spectively). The median delay in starting therapy after
diagnosis of sepsis was 24 h in the overall post-surgical
group and 48 h in the medical group. We did not observe
any device-related adverse events and there were no prob-
lems installing the adsorber in the pre-hemofilter position.
Discussion
In the present case series, we treated severely ill patients
with septic shock (APACHE II >25) who had two or more
organ failures, including CRRT-dependent renal failure,
with a combination of CVVHD plus hemoadsorption.
Treatment was associated with rapid hemodynamic
stabilization and a decrease in blood lactate. Mortality in
the overall patient population was lower than mortality
predicted by APACHE II scores. These effects seemed to
be more pronounced in patients in whom therapy started
within 24 h of sepsis diagnosis. Non-survivors had a
greater delay in starting therapy (>48 h), were older, and
had a poorer response to therapy in terms of reduction in
catecholamine demand within a certain time frame. More-
over, among our patient population, medical patients
seemed to benefit more than post-surgical patients in
terms of survival.
Albeit this study is descriptive only, we observed re-
versal in shock (defined as free from catecholamines or a
decrease to 10% of the maximum dose) in 38.5% of our
patients, and all those who had a clear decrease in cat-
echolamine demand during the course of their CytoSorb
treatment(s) survived to day 28 and survived their stay
in ICU. This is in line with as yet unpublished but pub-
licly presented data from a study in a subset of patients
with refractory septic shock at University Greifswald,
Germany, in which a considerable number of patients
were rescued from a life-threatening situation. Interest-
ingly, ICU survivors (n = 7) spent 68.29% of their ICU
stay catecholamine-free, whereas on average, non-
survivors spent only 7.5% of their ICU stay free from
catecholamines.
Fig. 3 Relationship between delay in starting therapy and the
severity of illness using the acute physiology and chronic health
evaluation II (APACHE II), simplified acute physiology score II (SAPS II)
and sequential organ failure assessment (SOFA) score before (pre)
treatment. In each Tukey boxplot the whiskers have equal lengths of
1.5 IQR. Dots represent outliers
Table 3 Association between delay in start of therapy and mortality (i.e. predicted mortality, 28-day, ICU, and hospital mortality) in
the overall patient population and in post-surgical and medical patients
Predicted mortality 28-Day mortality ICU mortality Hospital mortality
Delay in starting therapy <24 h (n = 13) 92.3 53.8 69.2 69.2
<48 h (n = 8) 82.1 62.5 75.0 87.5
>48 h (n = 5) 97.1 80.0 80.0 100.0
Focus Abdominal/post-surgical 92.3 69.2 76.9 84.6
Pneumonic/medical 87.0 53.8 69.2 76.9
Results are presented as median values
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Our findings, therefore, are in line with several experi-
mental and clinical data mostly from case reports and
case series, which have suggested that CytoSorb might
be an effective rescue therapy, stabilizing hemodynamics,
decreasing vasopressor requirements, and improving
lactate clearance in the setting of septic shock and post-
cardiopulmonary bypass SIRS [22–25].
Our indication for CytoSorb therapy is comparable to
the former indications in the PROWESS trial for acti-
vated, recombinant human protein C (drotegocin alfa
activated). These criteria included at least two organ fail-
ures with an APACHE II score >25, and no decrease in
the requirement for norepinephrine in spite of adequate
therapy over 24 h. Of note, the APACHE II score in our
subset of patients was relatively high (median 35) when
compared to other studies such as the PROWESS [20]
or MAXSEP trial [26], in which mean APACHE II scores
were 24.6 and 21.6, respectively. Our set of patients with
a median APACHE II score of 35 was predicted to have
a mortality rate of 89.9%. Importantly, in our study the
observed 28-day, ICU and hospital mortality was
61.54%, 73.08% and 80.77%, respectively.
We did not observe a clear improvement in SOFA
scores. However, as SOFA is a morbidity severity score
that relies in part on laboratory data, which may be de-
layed, and in which the organ function parameters may
also be slow to reflect improvement in those organs, it
did not reflect the real improvement in our patients
[27]. Supporting this line of argument is the fact that pa-
tients treated early in our study had a median SOFA
score of 11 at the start of treatment, whereas patients
with intermediate (24–48 hours) and late (>48 hours)
start of treatment had SOFA scores of 14.5 and 14, re-
spectively, pointing towards a manifestation of organ
dysfunction over time. Therefore, it might be reasonable
to suggest that a longer period of observation of the
SOFA scores might have been superior and should be
considered in future studies. Moreover, renal retention
parameters, as an integral part of the SOFA score, are
influenced by dialysis.
A recent blinded, randomized, controlled pilot study
examining the potential benefits of the CytoSorb ad-
sorber in patients undergoing cardiopulmonary bypass
(CPB) surgery found only minimal differences between
the treated patients and the control group [28]. How-
ever, these were patients with only low or moderately in-
creased risk, and who had no signs of uncontrolled
hyperinflammation, either intraoperatively or postopera-
tively. Therefore, their predicted mortality was relatively
low. On the contrary, patients in our study were severely
ill with probability of mortality of up to 90%. It is
assumed that Cytosorb treatment was beneficial in this
cohort, as reflected by the lower observed compared to
predicted mortality rate. This important difference
illustrates that the true benefit of such a new treatment
option, along with many others, depends on the choice
of appropriate patients with appropriate indications. It
further underlines why inappropriate patient selection
may be responsible for the neutral or negative results in
previous studies, and may have resulted in the removal
of potentially effective therapies from the market [29].
Although the concept of early goal-directed therapy
[7] remains a controversial topic [30, 31] and despite the
fact that the original data were generated in a trial that
originated in the emergency department, there could be
a direct advantage in early protocol-based treatment
(volume therapy, inotropy and transfusion). Similarly,
early antibiotic treatment [32] has also been positively
associated with survival. It is therefore not surprising
that early application of other therapies in comparable
patient groups have also shown potential advantages.
In fact, observations in our patients imply that starting
therapy no later than 24 h after diagnosis of septic shock
might be beneficial. Whether other patients could profit
from this adjunctive treatment is uncertain. As with
other therapies, it is of utmost importance to have the
appropriate patient selection, timing of the start of ther-
apy and the treatment duration in order to elucidate the
true benefits of this new treatment option.
Limitations
There are several limitations associated with this case
series. First and most important, this is a purely descrip-
tive case series. The lack of a control arm and the use of
multiple interventions (i.e. CytoSorb, CVVHD, antibi-
otics, vasopressors etc.) to treat these patients with com-
plex conditions makes it impossible to draw any definite
conclusions from the data collected. A second significant
limitation of this case series is the small number of pa-
tients and the fact that not all values were available for
all time points due to the retrospective nature of this
study analysis. Third, the follow-up period was relatively
short (up to hospital discharge), therefore it is hard to
validate whether the treatment might offer any long-
term benefits. Last, we did not perform cytokine mea-
surements, which is the main target of the adsorber, as
these types of measurements are not routine in our
institution.
The reasons for delay in starting therapy in our pa-
tients were numerous and included the late onset of
renal failure when CRRT was not necessary earlier, or
the late admission of the patient to the ICU. Further-
more, delay in making a definite diagnosis (either in the
ward or in the ICU), and the fact that this therapy op-
tion was not commonly known to all of the physicians
also resulted in further delay. All of these limitations
need to be considered in the design of upcoming trials.
Furthermore, one might argue that with our kind of
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protocol, to wait for acute renal failure to occur
might result in patients having a high probability of
failure to respond to therapy. In fact, the mortality
rate in AKI as part of multiple organ failure in the
setting of sepsis is 76% [33].
Another concern could be whether we treated patients
who would have survived without treatment anyway, if
we treated those without AKI. This objection is an im-
portant issue and can be only sufficiently addressed by
randomized controlled trials. Likewise, the question as
to what is the appropriate dosage and duration of ther-
apy remains unanswered, though it seems reasonable
from the data gained so far that treatment should be
continued until hemodynamic stabilization is achieved.
Conclusion
To our knowledge this is the first case series reporting
the use of CytoSorb therapy in severely ill patients with
septic shock of two different origins. Treatment of these
patients with a combination of CytoSorb and CVVHD
was associated with clear stabilization in hemodynamics
and concomitant decrease in vasopressor doses. Ob-
served mortality in the overall patient population was
lower than the mortality predicted by APACHE II
scores. These favorable effects seem to be more pro-
nounced in patients in whom therapy was started early
after diagnosis of sepsis, whereas a delay in starting ther-
apy was associated with a poor response to therapy in
terms of reduction in catecholamine-demand and poor
survival. Therefore, starting therapy early (preferably
within less than 24 h after onset of septic shock) seems
to potentially have advantages in terms of survival, and
non-surgical, medical patients seem to benefit more.
Treatment using the CytoSorb device was safe and well-
tolerated with no device-related adverse events during
or after the treatment sessions. Given the positive clin-
ical experience of this case series, randomized controlled
trials are urgently needed to define the potential benefits
of this new treatment option.
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